The Centre for Commercialization of Regenerative Medicine Australia (CCRM Australia) is proud to partner with Therapeutic Innovation Australia (TIA) to jointly develop an information system to curate data
CCRM Australia is proud to introduce, along with the IMNIS (Industry Mentoring Network in STEM), Australia’s first international mentoring program designed for Australian PhD students in regenerative medicine.
Nerve (neuropathic) pain affects one in twenty Australians. For some, it’s a frustration, for others it’s nothing short of debilitating. What’s worse, nerve damage often cannot be entirely
Whether you’re an industry member, an academic or an investor, networks and connections are a vital component of success in the field of regenerative medicine (RM) and CCRM
Networking, like science, requires time, effort and confidence. However, networking, unlike science, rarely earns a place in the curriculum. Despite the importance it plays in the establishment of
Australia’s regenerative medicine research output is world-renowned, as evidenced by not only the volume of publications in high-impact journals but also the number of emerging biotech companies. As
In 2008, mesenchymal stem cells were not gracing the front page of prestigious academic journals as they do today. Yet the founders of Regeneus knew differently. A company
As stem cell therapies move through clinical trials and get closer to the clinic, they are giving rise to new challenges, primarily around costs and the likelihood of
From Biotech Daily, Friday February 9, 2018 By Tim Boreham ASX code: CYP Share price: 82 cents; Shares on issue: 90,057,248 Market cap: $73.8 million Chief executive officer: Dr
